Biomea Fusion, a clinical-stage diabetes and obesity medicines company, announced the presentation of new preclinical and clinical data for icovamenib, the company’s investigational oral menin inhibitor, at the… read more.
Valneva SE announced that the FDA and the U.S. Centers for Disease Control and Prevention (CDC), in a joint communication to the medical community, have recommended a pause… read more.
Soleno Therapeutics, Inc, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentations at the 2025 United In… read more.
Johnson & Johnson MedTech announced that results from the TARGET study have been published by CHEST Journal. This landmark study demonstrated that clinicians were able to reach small… read more.
Alexion, AstraZeneca Rare Disease, will present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at the European Academy of Neurology (EAN) Annual Congress in… read more.
NICE (UK): Molnupiravir is recommended as an option for treating mild to moderate COVID‑19 in adults who have a positive SARS‑CoV‑2 test, only if: i) they have 1… read more.
Atara Biotherapeutics, Inc. a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases,… read more.
BeiGene, Ltd announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued a positive opinion recommending approval of Tevimbra (tislelizumab), in combination with gemcitabine… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the marketing authorisation for Zoonotic Influenza Vaccine Seqirus. The marketing authorisation… read more.
Amgen announced full results from Part 1 of the Phase II study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type… read more.
Roche announced the launch of its Elecsys PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated… read more.
Clearside Biomedical, Inc, a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that the use of its… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
